New AIDS Drug Receives FDA Approval
WASHINGTON, DC-A new nucleotide analog has been passed by the US Food and Drug Administration (FDA) in an attempt to help the current list of anti-viral AIDS drugs.
Viread, manufactured by Gilead Sciences of Foster City, Calif., was created to help fight against the rapidly mutating virus that has managed to create a resistance to many current AIDS drugs. The once-a-day pill will be available by week's end. Side effects include moderate diarrhea, nausea, vomiting, and flatulence.
In clinical trials of the drug, AIDS patients were found to have significant reduction in the amount of HIV cells in their bloodstream.
Viread is also known as tenofovir disoproxil fumarate.
Information from www.sfgate.com
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.
